ClinicalTrials.gg
RecruitingNCT07864896Updated Oct 13, 2026

Suzetrigine in TKA

A Phase 3 interventional study of Placebo and Suzetrigine in Total Knee Arthroplasty (TKA), Total Knee Arthroplasty \(TKA\) and Total Knee Replacement, sponsored by Hospital for Special Surgery, New York. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Hospital for Special Surgery, New York · Phase 3, Interventional, and Treatment

How we know

Updated Oct 13, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.

Planned enrollment
3rd of 21
148 · median 50
Started
2026
with 5 others
Phase 3
3 of 21
2 open now
Registered
20th of 21
by date
Lead sponsor
2 of 21
Hospital for Special Surgery, New York

Among the 21 studies testing suzetrigine in Pain, this one is the 3rd largest by planned enrollment, is one of 6 that started in 2026, is one of 3 in phase 3, and was the 20th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing suzetrigine in Pain, or all of them as a file.
02

Study summary

Total knee replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of suzetrigine's efficacy in total knee replacement is of high clinical value. In this confirmatory (phase III) trial, patients undergoing primary total knee replacement will be randomized to receive either suzetrigine or placebo for 2 weeks (14 days), with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).

03

Conditions studied

  • Total Knee Arthroplasty (TKA)
  • Total Knee Arthroplasty \(TKA\)
  • Total Knee Replacement
  • Total Knee Replacement Surgery
  • Total Knee Replacements
  • Total Knee Replacement Arthroplasty
  • Suzetrigine
  • Pain Management
  • Pain
  • Nav 1.8
  • JOURNAVX
  • Opioid Cessation
  • Opioid Consumption, Postoperative
  • Multimodal Analgesia
  • Randomized Controlled Trial
  • Randomized Controlled Study
  • Randomized Controlled Trials

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing primary TKA with participating surgeons
  • Age 18 to 80 years old
  • Planned Discharge to home
  • Planned use of neuraxial anesthesia
  • (ASA) Physical Status 1 - 3
  • Patients undergoing primary unilateral TKA with participating surgeons

Exclusion criteria

Exclusion Criteria:

  • ASA greater than 3
  • Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)
  • History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)
  • History of
  • Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device
  • Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse
  • Inability to comply with any component of the study protocol
  • Younger than 18 or greater than 80 years old at the time of enrollment
  • Patient already on Suzetrigine
  • Allergy or to Suzetrigine or (eg moderate to severe liver disease/ B or C, use of strong CYP3 inhibitors or inducers)
  • Contraindications to neuraxial anesthesia or any other part of the study protocol
  • Participation in another drug or device study
  • Pregnancy
  • Prior osteotomy of the operative knee
  • Baseline knee flexion \<60°
  • History of infection or septic arthritis of the operative knee
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
148 participants (estimated)

Study arms

  • Placebo comparator
    Placebo arm

    Other: Placebo

  • Experimental
    Suzetrigine

    Drug: Suzetrigine

Interventions

  • OtherPlacebo

    This will be a placebo drug.

  • Suzetrigine is a new novel peripherally acting non-opioid pain medication recently approved by the FDA that exerts its analgesic effects by binding to the peripherally located Nav1.8 Sodium channel receptors present on peripheral nerves.

06

What researchers measure

Primary outcomes

  1. Cumulative opioid consumption within the first 48 hours after TKA starting from post-anesthesia care unit entry (t=0), in oral morphine equivalents (OME)

    Time frame: From entry into the post-anesthesia care unit (PACU) to 48 hours after THA surgery

Secondary outcomes

  1. NRS (current at rest, with ambulation, worst & least in last 24 hours) Post-Operative Day (POD) 1-14

    Time frame: From admission to the Post Anesthesia Care Unit (PACU) through 14 days postoperatively (Post-Op Day 14)

  2. Numeric Rating Scale - post-anesthesia care unit: average, least, worst

    Numeric Rating Scale in Post-Anesthesia Care Unit (PACU) ranging from average to least to worst. Post operative pain using Numeric Rating Scale(current at rest, with ambulation, worst \& least in last 24 hours). The Numeric Rating Scale is a simple, widely used tool for measuring pain intensity. It consists of a 0-10 point scale. This will be measured after surgery in the PACU.

    Time frame: From arrival in PACU until discharge criteria are met (expected duration up to 2 hours postoperatively).

  3. Numeric Rating Scale @Post-Operative Day14, @week 6, @week 12 - average pain, worst & least: last 7 days; current

    Numeric Rating Scale measured at 14 days following surgery, then at 6 weeks following surgery and then 12 weeks following surgery. Measurements will range from average pain to worst pain to least amount of pain over the last 7 days and current pain.

    Time frame: From 14 days following surgery, 6 weeks from surgery and 12 weeks from surgery.

  4. Cumulative Opioid consumption (Oral morphine equivalents = OME): post-anesthesia care unit, 0-24hours, 0 to 168 hours (7 days postoperatively) 0-Post-Operative Day14

    Cumulative Opioid consumption (Oral morphine equivalents = OME): Post anesthesia care unit (PACU) at 0 and 24hours, 168 hours, and 14 days (i.e. 7 days postoperatively). The primary outcome is cumulative consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU). This measure will be taken from EPIC via the MAR and documented in the study "MUD"; post-discharge, patient to report date/time of opioid use # of pills, dose in diary and documented in study "MUD". Measurements will be taken in PACU, 0-24hrs, 0-48 hrs and 0-168hrs following surgery.

    Time frame: from first time in PACU to 24hours after, then 168hours after, and to 14 days after

  5. Opioid-free patients through Post-Operative Day2 (0-48hrs), Post-Operative Day7 (0-168hrs), Post-Operative Day14 (0-day 14)

    Patients that no longer require opioid medications at Postoperative day 2 (48hrs), 7 (168hrs) and 14

    Time frame: From start of trial to post operative day 2, 7 and 14

  6. Currently taking opioids & Opioid refills (Y/N, assessed @Post-Operative Day14, @6 week, @12 week)

    If patient is currently taking opioids or getting Opioid prescription refills, answered as either yes or no and assessed on post operative day 14, at week 6 and week 12 following surgery.

    Time frame: From surgery to post operative day 14 week 6 and week 12

  7. Non-opioid analgesic use (Post-Operative Day0-48 hrs, 0-168 hrs, 0-Post-Operative Day14)

    Analgesics used other than opioids on day of surgery, postoperative day 2 (i.e. 48 hrs), day 7 (i.e. 168hrs), and day 14

    Time frame: From day of surgery to 48hours after,168hours after, and 14 days after

  8. Study medication discontinuation (% of patients who stopped the placebo/Suzetrigine day 0 through post-op day 14)

    The percentage of patients who patients who stopped taking either the placebo drug or Suzetrigine within the first 14 days following surgery

    Time frame: From surgery to the 14th day post operatively

  9. Request for Suzetrigine refill after randomization period

    Number of patients that requested more or a refill of Suzetrigine after the randomization period was over

    Time frame: From date if surgery till until end of study up to 2 years after surgery

  10. Patient satisfaction with pain management: @ Post-Operative Day2 and @Post-Operative Day7 and @Post-Operative Day14

    Patients will communicate there satisfaction with how well their pain is controlled this will be assessed 2 days and 7 days and 14 days following surgery. Number on Scale out of 10 (where 0 is not satisfied, 10 is very satisfied).

    Time frame: From date of surgery to 2 days following surgery and then again 7 days following surgery and 14 days following surgery.

  11. Pain Interference: @Post-Operative Day2 and @ Post-Operative Day7 and @Post-Operative Day14

    Measuring how much since surgery Pain has interfered with normal day to day activities. This will be self reported using a number Scale (0-10, 0= no interference, 10= significant interference) on postoperative days 2 and 7 and 14. Patients will be asked; how much, since your surgery, has pain interfered with performing activities in bed such as turning, sitting up, and changing position? how much, since your surgery, has pain interfered with walking? how much, since your surgery, has pain interfered with your sleep? how much, since your surgery, has pain interfered with your mood?

    Time frame: From date of surgery to post operative day 2 and 7 and 14

  12. KOOS, JR @ 6 weeks

    Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, JR) is a 0-100 scale that assesses hip pain and function, where a higher score indicates better hip health and a lower score indicates greater disability. This will be assessed preoperatively within 30 days of the surgery and then again 6 weeks post operatively. This measure will be extracted via EPIC or by a patient reported survey if not filled out in EPIC/mychart.

    Time frame: Up to 30 days preoperatively to 6 weeks following surgery

  13. Sleep quality & @preop, Post-Operative Day7 and Post-Operative Day14 (questionnaire asks about sleep quality/duration over the past week)

    Sleep quality will be assessed using patient-reported questionnaires that evaluate sleep patterns over the preceding week. Assessments will be completed preoperatively and on postoperative days 7 and 14. Outcomes will include overall sleep quality rating and average sleep duration in hours per night.

    Time frame: Pre-op and Post-Operative Day (POD)7 and Post-Operative Day (POD)14

  14. Incidence of adverse invents (Post-Operative Day0-14)

    Unexpected adverse events, that may occur to the patient after administration of Suzetrigine from the date the medication is given to the 14th day following surgery using Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0) grading system Grade 1 Mild; Grade 2 Moderate; Grade 3 Severe or medically significant; Grade 4 Life-threatening consequences; Grade 5 Death related to AE. for Nausea, Vomiting, Constipation, Difficulty passing urine, Concentrating, Somnolence, Lightheaded/dizziness, Confusion, Fatigue, Pruritis, Headache, Dry mouth, Paresthesia, Muscle spasm, Rashes, Problems with sleep, Delirium, Abnormal lab values, Other Patient-reported adverse effects (diarrhea, changes to heart beat/arrythmias, blurred vision, low blood pressure, difficulty breathing, hives, swelling of the face/lips/tongue/extremities/throat, other)

    Time frame: From the date the medication is given to the post operative day 14.

  15. Patient expectation of Suzetrigine @preop

    Patient expectations regarding the effectiveness of Suzetrigine for postoperative pain management will be assessed prior to surgery using a questionnaire. Patients will report their anticipated level of pain relief, improvement in function, reduction in opioid requirements, and overall confidence in the medication.

    Time frame: Pre-op

  16. Block duration assessed @Post-Operative Day1, (or Post-Operative Day2 or until full resolution)

    Duration of peripheral nerve block will be assessed from the time of block administration until complete resolution of sensory and motor blockade. Resolution will be determined through patient report and clinical assessment of return of normal sensation and motor function.

    Time frame: Postoperative day 1 or until complete resolution of sensory and motor blockade assessed for up to 14 days postoperatively

  17. Range of Motion (ROM) @week 6

    Knee range of motion (ROM) will be measured at 6 weeks following surgery using standard clinical assessment techniques. ROM will be recorded in degrees and include measurements of both knee flexion and extension. Higher flexion and lower extension deficits indicate improved postoperative joint function.

    Time frame: 6 weeks post operative

  18. Rate of manipulation under anesthesia (MUA) through 6 weeks and through 12 weeks

    The rate of manipulation under anesthesia (MUA) performed for postoperative knee stiffness will be recorded through 6 weeks and 12 weeks after surgery. Incidence will be reported as the proportion of patients requiring MUA during the follow-up period.

    Time frame: Day of surgery to 12 weeks post-surgery

  19. duration @preop, Post-Operative Day7 and Post-Operative Day14 (questionnaire asks about sleep quality/duration over the past week)

    Sleep duration will be assessed using patient-reported questionnaires that evaluate sleep patterns over the preceding week. Assessments will be completed preoperatively and on postoperative days 7 and 14. Outcomes will include overall sleep quality rating and average sleep duration in hours per night.

    Time frame: Preop, Post-Operative Day (POD)7 and Post-Operative Day (POD) 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Requests for de-identified research data should be directed to the principal investigator Meghan Kirksey, MD, PhD at the email address: KirkseyM@hss.edu. A fully executed data use agreement between Hospital for Special Surgery and the requesting institution is required prior to data sharing.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2029, 27 months later.

Of 111 non-industry phase 3 interventional studies under Pain, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 27 months is close to that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Oct 8, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2030
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 7, 2026→Oct 15, 2026
Oct 13, 2026
Registered
First appeared on the registry
Oct 8, 2026
Show all 2 updates
  1. Oct 13, 2026
    Start date Oct 7, 2026→Oct 15, 2026
  2. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864896
Responsible party
Sponsor
First posted
Oct 8, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Oct 13, 2026

Study contacts

Curtis Weh, B.S.
Contact
wehc@hss.edu
917-260-3937
Hannah Gerner, MD
Contact
Gernerha@hss.edu
646-714-6509
Meghan Kirskey, MD
principal investigator · Department of Anesthesiology, Critical Care & Pain Management at the Hospital for Special Surgery
Alexandra Sideris, PhD
principal investigator · Department of Anesthesiology, Critical Care & Pain Management at the Hospital for Special Surgery

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion